Navigation Links
BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease
Date:9/17/2008

ree of penile curvature (i.e. 30 degrees to 60 degrees versus > 60 degrees) and then randomized into 4 treatment groups to receive either XIAFLEX or placebo with or without modeling of the penile plaque. Modeling refers to massaging of the plaque after the second injection of a treatment series and is intended to maximize the enzymatic effect of the XIAFLEX injection in the plaque. Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.

About Peyronie's Disease

Peyronie's disease is characterized by the presence of a collagen plaque on the shaft of the penis, which can distort an erection and make intercourse difficult or impossible in advanced cases. The plaque is not elastic and it does not stretch during erection. In some mild cases, the plaque can resolve spontaneously without medical intervention. The most common plaque forms on the top of the penis causing the penis to arc upward. In severe cases, the penis can be bent at a 90-degree angle during erection. Significant psychological distress has been noted in patients with Peyronie's disease who are sexually active. Frequent patient complaints include increased pain, painful erections, palpable plaque, penile deformity, and erectile dysfunction. Patients with Peyronie's disease have been reported to have an increased likelihood of having Dupuytren's disease, frozen shoulder, plantar fibromatosis, knuckle pads, hypertension and diabetes. Peyronie's disease typically affects males in the range of 40-70 years. The cause of Peyronie's disease is unknown, although some investigators have proposed that it may be due to trauma or an autoimmune component. A number of researchers have suggested that the incidence of Peyronie's disease has increased due to the use of erectile dysfunction drugs.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and lic
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
2. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
3. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
4. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
5. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
6. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
7. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
8. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
9. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
10. Wound Management Technologies, Inc. Announces Evidence Based Study
11. Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 CVS Caremark Corporation (NYSE: CVS ... Executive Officer, will be making a presentation to investors ... June 1, 2011. Mr. Merlo is scheduled to present ... An audio webcast of the presentation will be ...
... U.S. Food and Drug Administration today approved Edurant (rilpivirine) ... of HIV-1 infection in adults who have never taken ... ) Edurant belongs to a class ... The drug works by blocking HIV viral replication. Edurant ...
Cached Medicine Technology:FDA Approves New HIV Treatment 2FDA Approves New HIV Treatment 3
(Date:12/21/2014)... 2014 SCI explores disability ... and systemic barriers for disabled athletes with Aaron ... has a condition called juvenile macular degeneration, where he ... he adapted his athletic ambitions to his vision and ... triathlon to pioneer the way for other blind and ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... and blood clots from using testosterone products such as ... shows that the male hormone testosterone may increase the ... published in the Proceedings of the National Academy of ... group of male rats with naturally occurring colon cancer. ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted their third ... The Hope for the Holidays Toy Drive is a way ... during the holiday season. This year, the toy drive was ... offices. This event continues to be successful year after year. ... managers and assistant managers came out and not only donated ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... 2014 MissyDress, a distinguished special dress ... lovers. The business has drastically cut prices to all ... everyone until Jan. 30, 2015. Many of the hottest ... V-neck dresses, lace dresses, and more. , A spokesman ... every day. Whether A-line princess prom dresses or sweetheart ...
Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... FRANCISCO, March 9 Medivation, Inc. (Nasdaq: ... host a teleconference and webcast with management to discuss fourth ... business update on Monday, March 16, 2009, at 4:30 p.m. ... year ended December 31, 2008 will be released after markets ...
... March 9 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... hearing to appeal to a Listings Qualification Panel ("Panel") ... the Company,s common stock from The Nasdaq Capital Market ... requires the Company to have a minimum of $2,500,000 ...
... In Kentucky, nearly one out of every two ... barely a quarter of the dentists accept the insurance; ... when it comes to seeing a dentist or receiving ... Consumer Healthcare, manufacturer of Aquafresh(R) and Sensodyne(R), has donated ...
... risk by 45%, study finds, , , MONDAY, March 9 (HealthDay News) ... of gout, according to researchers who studied almost 47,000 men over ... the men developed gout. Compared with those whose vitamin C intake ... the risk for gout was 17 percent lower among men with ...
... care, closure important for dying, families and docs, study finds, ... more that can be done for terminally ill patients, and ... death, many feel as if their doctors have abandoned them, ... their families, continuing care is helpful for all concerned, and ...
... forensics cameras will survive., , , ... , , , ... , , , ... , , , Lights, Camera, Ka-Boom! , Cheap, ...
Cached Medicine News:Health News:Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 2Health News:Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq 3Health News:GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia 2Health News:More Vitamin C May Mean Less Chance of Gout 2Health News:Dying Feel Abandoned by Docs in the End 2Health News:Dying Feel Abandoned by Docs in the End 3Health News:Ka-Boom!!! 2Health News:Ka-Boom!!! 3Health News:Ka-Boom!!! 4
Large....
These products are supplied non-sterile and must be sterilized before use. For insertion through the smokevac and nezhat-dorsey trumpet valve in conjunction with the universal instrument insert adapt...
... Utilizing breakthrough electro-optical and rotary ... SUPRA is capable of obtaining ... pupils as narrow as 2.0mm. ... precise diagnostic results when dealing ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: